For patients transitioning from rituximab to ravulizumab, meningococcal vaccination can be safely done within 6 months after ...

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

Children with rheumatic diseases may face increased risks for COVID-19-related hospitalization, particularly those using glucocorticoids, rituximab, or mycophenolate.

STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S.

In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

A study suggests a simple treatment algorithm can help reduce racial and ethnic disparities in MS care by increasing the use of highly effective therapies.

A new study published in the journal of BMC Nephrology revealed rituximab to be an effective and safe steroid sparing medication in individuals with steroid dependent (SD)/frequent relapsing ...

Progression-free survival significantly lower with fixed-duration acalabrutinib-venetoclax with or without obinutuzumab.

A simple treatment algorithm to aid in the selection of appropriate DMTs reduces racial disparities in patients with ...

OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for interchangeability was supported by positive phase III data demonstrating comparable ...

A simple algorithm to recommend disease-modifying therapies may help reduce racial and ethnic inequalities in MS treatment, per a study.

Japanese drugmaker Kyowa Kirin and Swiss generics and biosimilars giant Sandoz have won approval for the partial change of their rituximab biosimilar for the treatment of refractory nephrotic syndrome ...